EMILIA · 2012 · New England Journal of Medicine
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
T-DM1 improves progression-free and overall survival vs.
Source publication
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al. · New England Journal of Medicine · 2012
Sponsor
Hoffmann-La Roche
Principal investigator
Clinical Trials
Population
Breast Cancer; n=991
Primary endpoint
Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)
Methodology notes
Full methodology is under curation. This project aggregates 3 seeded claims across three temporal layers. The replication spec, pre-registered analysis, and version history will appear here as the project matures.
Funding progress
$1.7M / $4.5M
37%
Funding displayed here is indicative of collaborator interest. Sciync does not broker money, grants, or securities.
Temporal layers
Published findings under validation
1
Active replication in progress
1
Forecast horizons pending resolution
1